Gastrointestinal distress Semaglutide can cause gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, stomach pain, bloating, belching, loss of appetite, and upset stomach
GLP-1s Improve Liver-Driven Heart Risk Think of the liver as the bodys primary refinery
The weight reductions were accompanied by cardiometabolic profile improvements: decrease in waist circumference, lower systolic and diastolic blood pressure, improved glycemic control including fasting glucose and HbA1c and lower lipid levels
Food and Drug Administration first approved semaglutide as Ozempic for type 2 diabetes in 2017 and as Wegovy for chronic weight management in 2021, and approved tirzepatide as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023
Weight Loss participates receive BIG discounts on our Skinny IV Drip and Hydration IV Drip
While these botanicals may offer metabolic benefits, they can further reduce glucose levels when taken alongside GLP-1 medications